Form 4: NeuroOne CEO Sells Shares for Tax Obligations

NeuroOne Medical Technologies CEO David A. Rosa disposed of 2,458 shares of common stock to cover tax liabilities.

Summary

• David A. Rosa, CEO and President, and a Director and 10% Owner of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC), reported a transaction.
• On March 31, 2026, Mr. Rosa disposed of 2,458 shares of common stock.
• The transaction was executed at a price of $0.777 per share.
• This disposition was made to satisfy tax withholding obligations, indicated by transaction code 'F'.
• Following this transaction, Mr. Rosa beneficially owns 1,080,132 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the disposition of shares is a routine transaction for tax withholding purposes and does not reflect a change in the company's operational performance or strategic direction.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider trading activity and typically do not provide insights into broader industry trends or competitive landscape, focusing solely on individual ownership changes.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, which is a routine event for tax purposes and generally has minimal impact on overall shareholder sentiment or company valuation.

Key Dates

Keywords

NeuroOne Medical Technologies, NMTC, Form 4, Insider Transaction, David A. Rosa, Stock Sale, Tax Withholding